XP5 is a potent and orally active HDAC6 inhibitor (IC50 = 31 nM) with high antiproliferative activity against various cancer cell lines, including HDACi-resistant YCC3/7 gastric cancer cells (IC50 = 0.16–2.31 μM); it enhances antitumor immunity when combined with a PD-L1 inhibitor in melanoma.